Ezharmia gets new approval in Japan for PTCL

Japanese drugmaker Daiichi Sankyo’s (TYO: 4568) Ezharmia (valemetostat tosilate) has been approved in Japan for the treatment of adult patients with relapsed or refractory peripheral T-cell lymphoma (PTCL).

Ezharmia is now the first dual inhibitor of EZH1 and EZH2 to be approved for PTCL after receiving SAKIGAKE  designation for this indication, the company noted.

Daiichi Sankyo explained that PTCL is a group of rare and often aggressive blood cancers, which represent about 10 to 15% of all non-Hodgkin lymphomas (NHL). PTCL is more common in Asia, including in Japan, compared to other parts of the world. A majority of patients with PTCL experience disease progression following initial treatment with a multi-drug chemotherapy-based regimen and median overall survival following relapse is approximately 5.8 months.1